Research programme: insulin sensitisers - Incyte Corporation
Alternative Names: insulin sensitisers research programme - Incyte Corporation; MX 6054; MX 6198Latest Information Update: 23 Aug 2006
Price :
$50 *
At a glance
- Originator Incyte Corporation
- Developer Incyte Corporation; Johnson & Johnson Pharmaceutical Research & Development LLC; Ortho-McNeil
- Class Small molecules
- Mechanism of Action Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 14 Oct 2003 This programme is still in active development
- 03 Mar 2003 Maxia Pharmaceuticals has been acquired by Incyte Genomics